androstenediol has been researched along with fulvestrant in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bellavance, E; Luu-The, V; Poirier, D | 1 |
| Alexi, X; Alexis, MN; Avlonitis, N; Calogeropoulou, T; Charalampopoulos, I; Gravanis, A; Katsanou, ES; Lazaridis, I; Minas, V; Pantzou, A; Vergou, V; Zervou, M | 1 |
2 other study(ies) available for androstenediol and fulvestrant
| Article | Year |
|---|---|
Potent and selective steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 7, an enzyme that catalyzes the reduction of the key hormones estrone and dihydrotestosterone.
Topics: 17-Hydroxysteroid Dehydrogenases; Androstane-3,17-diol; Androstanes; Biocatalysis; Cell Line; Dihydrotestosterone; Enzyme Inhibitors; Estradiol; Estrone; Humans; Inhibitory Concentration 50; Oxidation-Reduction; Substrate Specificity | 2009 |
Novel dehydroepiandrosterone derivatives with antiapoptotic, neuroprotective activity.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Dehydroepiandrosterone; Estrogen Receptor alpha; Estrogen Receptor beta; Humans; Models, Molecular; Molecular Conformation; Neurons; Neuroprotective Agents; Rats; Structure-Activity Relationship | 2009 |